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Abstract Angiogenesis inhibitors have long been considered
desirable anticancer agents. However, it was found that many
tumors could develop resistance to antiangiogenesis inhibi-
tors. Antiangiogenic therapy results in metabolic stress.
Autophagy is an important survival mechanism in cancer cells
under metabolic stress; however, it remains unknown if
autophagy contributes to antiangiogenesis resistance. In this
study, we reported that bevacizumab treatment reduced the
development of new blood vessels and inhibited cell growth in
xenografts of hepatocellular carcinoma (HCC) tumors. Bev-
acizumab treatment also upregulated expression of the
autophagy-related genes (Beclin1 and LC3) and increased
autophagosome formation. Our in vitro studies demonstrated
that autophagy inhibition significantly increased apoptosis of
HCC cells during nutrient starvation or hypoxia. In addition,
the combined treatment of an autophagy inhibitor and bev-
acizumab markedly inhibited the tumor growth of HCC
xenografts, led to enhanced apoptosis, and impaired the pro-
liferation of tumor cells compared with treatment with either
drug alone. Furthermore, autophagy inhibition led to en-
hanced reactive oxygen species (ROS) generation in HCC
cells exposed to nutrient starvation or hypoxia in vitro and
increased DNA oxidative damage in vivo. Antioxidants re-
duced nutrient starvation or the hypoxia-induced cell death of
HCC cells after autophagy inhibition. Our results suggest that
autophagy modulates ROS generation and contributes to cell
survival under metabolic stress. Therefore, autophagy inhibi-
tion may be a novel way of increasing the efficicacy of
antiangiogenic agents in the treatment of HCC.
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Introduction
Hepatocarcinoma (HCC) is a hypervascular tumor character-
ized by neovascularization. Its growth relies on the formation of
new blood vessels [1]. Vascular endothelial growth factor
(VEGF) expression is upregulated in HCC compared with the
cirrhotic or normal liver [2, 3]. These findings strongly suggest
that antiangiogenic strategy may be therapeutically beneficial in
the management of HCC. The effects of several antiangiogenic
agents, including bevacizumab, have been evaluated in preclin-
ical studies. Bevacizumab is a recombinant, humanized mono-
clonal antibody that binds VEGF with high affinity and has
been approved by the FDA for treatment of certain late-stage
cancers [4, 5]. Several studies have explored the clinical effica-
cy of bevacizumab in patients with advanced HCC; however,
its therapeutic effects have not been satisfied [6].
Autophagy is an evolutionarily conserved mechanism that
exists in all eukaryotes from yeast to mammals [7]. During
autophagy, a double membrane, known as the isolation
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membrane, wraps around portions of the cytoplasm and intra-
cellular organelles to form a double-membrane vesicle called
autophagosome. Upon maturation, autophagosomes fuse with
lysosomes to form autolysosomes and are degraded by lyso-
somal proteases [8, 9]. In addition to its homeostatic role, the
autophagic process allows cells to survive nutrient stress, by
providing amino acids and fatty acids to maintain metabolic
levels. The genes that regulate autophagy were first identified in
yeasts, many of which have homologues in higher eukaryotes
[10]. Among them, LC3 [11] and Beclin1 [12] are widely used
as markers of autophagy.
Antiangiogenic therapy leads to nutrient deprivation and
oxygen stress in solid tumors; autophagy helps cells cope with
these unfavorable conditions. Therfore, we hypothesized that
autophagy inhibition could enhance the therapeutic efficacy of
antiangiogenic treatments. To test this, we investigated the
effect of bevacizumab on autophagy and determined if auto-
phage inhibition could enhance the sensitivity of hepatocarci-
noma to bevacizumab treament.
Materials and methods
Cell culture and reagents
The human hepatocarcinoma cell lines, SMMC-7721 and
Hep3B, were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) (GIBCO, Invitrogen) and supplemented with
10 % fetal bovine serum at 37 °C in a humidified 5 % CO2
incubator. Nutrient deprivation was carried out in Earle’s bal-
anced salts (EBSS) medium (Sigma-Aldrich). 3-Methyladenine
(3-MA), chloroquine (CQ), and N-acetyl-cysteine (NAC) were
obtained from Sigma-Aldrich (Shanghai, China). Bevacizumab
was obtained from Roche (Shanghai, China).
Cell viability assay
The measurement of viable cell mass was assessed by a Cell
Counting Kit (Dojin Laboratories, Kumamoto, Japan), as
previously described [13].
Western blot analysis
Western blot analysis was performed as described [14].
Antibodies used were specific for Beclin1, LC3, HIF-1α,
and GAPDH (Epitomics, Inc.).
Immunohistochemical analysis
Excised tumor tissue specimens from nude mice were
formalin-fixed and embedded in paraffin. Sections 3–5 μm
thick were cut (n04 tumor sections from each tumor),
mounted, and stained with the following antibodies: rabbit
anti-CD31 (1:50; Bioworld Technology), rabbit anti-PCNA
(1:2,000; Bioworld Technology), rabbit anti-activated
caspase-3 (1:1,000; Bioworld Technology), rabbit anti-
Beclin1 (1:200; Novus Biologicals), rabbit anti-LC3
(1:200; Novus), mouse anti-HIF-1α (1:100; Santa Cruz),
and goat anti-8 hydroxyguanosine antibody (1:400,
Abcam). Horseradish peroxidase (HRP)-labeled goat anti-
rabbit immunoglobulin and HRP-labeled goat anti-mouse
immunoglobulin (Santa Cruz) were applied as secondary
antibodies for 30 min at 37 °C, followed by the streptavi-
din–biotin complex method. Immunostaining was devel-
oped with DAKO Liquid DAB+Substrate–Chromogen
System (Changdao BioTech), followed by counterstaining
with hematoxylin. PCNA-positive nuclei were counted in
five random fields per tumor (400×) and were expressed as
a percentage of the total number of cells observed in
each individual tumor. Activated caspase-3-positive cells
were counted in five random fields per tumor (200×).
Data were expressed as mean±standard deviation (SD).
Tumor tissue images were taken using the LEICA DM
RXA2 microscope.
TUNEL assay
Analysis of apoptotic cells in tumor tissue was performed by
terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) staining using the apoptotic cell detec-
tion kit following the manufacturer’s directions (Merck
Corp.). TUNEL-positive (apoptosis) cells had a pyknotic nu-
cleus with dark green fluorescent staining. Each sample was
observed at a magnification of 400×, and TUNEL-positive
cells were calculated in five random fields per tumor.
siRNA oligonucleotides and recombinant adenovirus
Stealth RNAiTM siRNA duplex oligoribonucleotides were used
as siRNAs to human Beclin1 [14]. The production of recombi-
nant adenovirus (Adsi-Beclin1) was performed as previously






GFP-LC3-expressing plasmids were transiently transfected
into HCC cells as previously described [14].
Cell apoptosis assay
Apoptosis detection by Annexin V/PI and DAPI staining
were performed as described [14].
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ROS examination
To examine the accumulation of reactive oxygen species (ROS),
cells were incubated with 10 μM 5- and-6-chloromethyl-20,70-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA/DCFH-
DA; Invitrogen) for 30 min at 37 °C, respectively, followed by
fluorescence microscopy.
In vivo studies
To establish a hepatocarcinoma xenograft tumor model,
SMMC7721 and Hep3B cells (2.0×107 cells in 0.2 ml
serum-free DMEM medium) were injected subcutaneously
into the right back of male athymic BALB/c nu/nu mice (5-
week-old). Tumor growth was monitored with electronic cal-
ipers using the formula: volume ¼ a b2=2, where a was the
width at the widest point of the tumor, and b was maximal
width. When the tumors reached a mean tumor volume of
150–160 mm3, mice were randomly divided into five groups
(each group had five mice) as follows: (a) control group (no
treatment); (b) vehicle group (0.9 % sodium chloride solution
or AdSi-blank); (c) bevacizumab group; (d) autophagy inhi-
bition (chloroquine or AdSi-Beclin1); (e) combination group.
Mice received intraperitoneal injections of 5 mg/kg bevacizu-
mab or 60 mg/kg CQ in 100 μl of 0.9 % sodium chloride
solution, or were treated with AdSi-Beclin1 or AdSi-blank
virus by way of multiple-center intratumoral injections of
50 μl thrice weekly. All BALB/c nude mice were killed after
3 weeks of treatment.
Statistical analysis
Values were expressed as mean±SD. Statistical analysis
between the two groups was calculated using Student’s t
test, and analysis between multiple groups was calculated
using the SPSS program, version 15.0. A p<0.05 was con-
sidered statistically significant.
Results
Effects of bevacizumab on xenograft tumors and autophagy
To evaluate the effect of antiangiogenesis on xenograft tumor
growth, bevacizumab was used as an antigiogentic agent. As
shown in Fig. 1a, after 21 days of treatment, the mean
SMMC7721 xenograft tumor weight of bevacizumab treatment
group was significantly reduced compared with that of the
control (1.16±0.15 g versus 1.61±0.28 g; p<0.05) and vehicle
(PBS) (1.16±0.15 g versus 1.57±0.26 g; p<0.05) groups
(Fig. 1a). The mean tumor volume of the bevacizumab group
was also markedly reduced compared with that of the control
(1,266.78±145.77 mm3 versus 1,695.63±194.74 mm3; p<0.05)
and vehicle (1,266.78±145.77 mm3 versus 1,652.24±
175.86 mm3; p<0.05) groups (Fig. 1b). In Hep3B xenograft
tumors, similar results were observed (Supplementary
Fig. 3a,3b). Moreover, CD31 immunohistochemical staining
showed lower microvessel density in the bevacizumab-treated
tumor (Fig. 1c). Additionally, the higher expression of HIF-1α
in bevacizumab-treated tumors suggested that bevacizumab
led to the enhancement of metabolic stress (Fig. 1c, d and
Supplementary Fig. 3c).
Antiangiogenesis treatment leads to hypoxia and nutrient
stress, both of which activate autophagy. Thus, we were
interested in determining the effect of bevacizumab on
autophagy in xenograft tumors. As shown in Fig. 1c and d,
expression of Beclin1 and LC3 were upregulated in the bev-
acizumab group compared with the control and vehicle
groups, which indicated activation of autophagy. Furthermore,
electron microscopy analysis demonstrated an increase in
autophagosomes in bevacizumab-treated tumors (Fig. 1e and
Supplementary Fig. 3c). However, bevacizumab (25 μg/ml)
could not activate autophagy in SMMC-7721 cells in vitro
(Fig. 1f). Taken together, these results demonstrated that bev-
acizumab repressed tumor growth, reduced microvessel den-
sity, and induced autophagy in xenograft tumors.
Inhibition of autophagy increases apoptosis
of hepatocarcinoma cells during nutrient starvation
and hypoxia in vitro
Reducing tumor vasculature by antiangiogenic agents leads to
nutrient starvation and hypoxia. These conditions of nutrient
deficiency activate autophagy. To evaluate the effect of
autophagy on nutrient deficiency in HCC cells, nutrient-
deprived medium and hypoxia were used to mimic the
nutrient-deficient condition, which tumor cells were exposed
to in vivo during bevacizumab treatment. First, SMMC7721
cells, transfected with a GFP-LC3 plasmid, were cultured in
nutrient-starved medium. As shown in Fig. 2a, nutrient-
starved SMMC7721 cells had a significantly increased num-
ber of GFP-LC3 dots, an indicator of autophagy activation.
This was enhanced by CQ treatment and attenuated by 3-MA.
The results of WTS-8 assay showed that 3-MA or CQ treat-
ment led to an increase in cell death (Fig. 2b). Cell morphol-
ogy detection demonstrated that typical apoptotic changes
appeared in 3-MA or CQ-treated nutrient-starved cells, in-
cluding marked rounding, shrinkage, and detachment of cells
from the culture dish (Fig. 2c). The results of DAPI and
Annexin V/PI staining also demonstrated that treatment with
autophagy inhibitor in nutrient-starved SMMC7721 cells in-
duced significantly more apoptosis (Fig. 2d, e). The same
results were also observed in Hep3B cells (Fig. 3). Taken
together, these data suggest that inhibition of autophagy
results in increased apoptosis in HCC cells during nutrient
starvation.
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To further confirm the role of the autophagicmachinery, we
used siRNA to inhibit the Beclin1 gene, which is essential for
autophagosome generation [16]. As shown in Supplementary
Fig. 1, silencing of Beclin1 markedly increased nutrient
starvation-induced apoptosis in HCC cells. Together, these
data strongly indicate that HCC cells resist nutrient
starvation-induced apoptosis by activating autophagy.
To test the protective role of autophagy on HCC cells during
hypoxia, SMMC7721 and Hep3B cells, transfected with either
no-target siRNA or Beclin1 siRNA, were cultured under nor-
moxia (20 % O2) or hypoxia (1 % O2) for 36 h. As shown in
Fig. 4a, d, and e, hypoxic HCC cells showed an increase in the
formation of GFP-LC3 dots, which was markedly inhibited by
siBeclin1. Moreover, siBeclin1 treatment significantly in-
creased apoptosis of hypoxic HCC cells (Fig. 4b, c, f, g). Thus,
our data demonstrated that autophagy promoted HCC cell
survival under hypoxic conditions.
Inhibition of autophagy promotes the anticancer effects
of bevacizumab in HCC xenograft tumors
To investigate the in vivo efficacy of the combined treatment of
an autophagy inhibitor and angiogenesis inhibitor in hepatocar-
cinoma, a SMMC-7721 hepatocarcinoma xenograft tumor
model was established in nude mice. As shown in Fig. 5a, the
increased accumulation of LC3 and formation of the autopha-
gosome were observed in the CQ and bevacizumab combina-
tion treatment group. These data suggest that CQ can
successfully inhibit autophagy in vivo. The results of CD31
staining also suggested that CQ had no effect on angiogensis in
xenograft tumors. Furthermore, there were no significant differ-
ences in the body weight of nude mice between groups
(Fig. 5b). After 21 days of treatment, the mean tumor volume
of the combination group was significantly reduced compared
with the bevacizumab group (818.68±152.52 mm3 versus
Fig. 1 Bevacizumab inhibits tumor growth and induces autophagy in
SMMC-7721 xenograft model. The tumor models are described in the
“Materials and methods” section. a After 21 days of treatment, the
tumor xenografts were excised, and tumor weights were measured.
Data (mean±SD) represent the mean of at least three independent
experiments. b Tumor progression was evaluated by measuring tumor
volume every 4 days. c Immunohistochemical staining of CD31,
Beclin1, LC3, and HIF-1α. d Whole cell lysates of SMMC-7721
xenograft tumors were subjected to Western blot analysis for Beclin1,
LC3, and HIF-1α. GAPDH expression was used as a loading control
(scale bar, 100 μm). Beva: bevacizumab. e Representative electron
microscopic images are shown. An arrow indicates the autophago-
some. f SMMC-7721 cells were transfected with a GFP-LC3 plasmid
and were then treated with vehicle and bevacizumab (25 μg/ml) for
24 h (scale bar, 50 μm). Representative images are shown (a). Whole
cell lysates were subject to Western blotting for LC3 (b)
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1,138.41±129.14 mm3; p<0.05; Fig. 5c). Meanwhile, com-
pared with the bevacizumab group, the mean tumor weight of
the combination group was significantly reduced by 27.46 %
(p<0.05; Fig. 5d). The same results were also observed in
Hep3B xenograft tumors (Supplementary Fig. 3a,3b). Together,
these results indicate that the combined treatment of CQ and
bevacizumab can significantly inhibit tumor growth in vivo.
Combination bevacizumab and chloroquine treatment
inhibits cell proliferation and increases intratumoral
apoptosis in HCC xenograft tumors
Metabolic stress has been reported to have the ability to induce
apoptosis [17]. To elucidate the potential mechanism underly-
ing the tumor-suppressive function of combined bevacizumab
and CQ treatment, we examined the proliferation and apoptosis
of xenograft tumor cells. Proliferating cell nuclear antigen
(PCNA) is a widely used marker of cell proliferation. As shown
in Fig. 6a and d, PCNA expression was significantly reduced in
the bevacizumab group compared with the control and vehicle
groups. In addition, a combination of bevacizumab and CQ
treatment further reduced PCNA expression when compared
with treatment with bevacizumab alone (47.35±2.51 % versus
59.26±3.52 %; p<0.05). To detect tumor cell apoptosis, acti-
vated caspase-3 immunostaining and TUNEL assay were per-
formed. As shown in Fig. 6b and e, activated caspase-3
expression was significantly upregulated in the combined bev-
acizumab and CQ treatment group compared with the bevaci-
zumab treatment group (37.67±3.21 % versus 23.32±2.88 %;
p<0.05). These results were further confirmed by the TUNEL
assay, which showed that combination of bevacizumab and
chloroquine treatment induced more apoptosis in tumor cells
than bevacizumab treatment alone (25.45±2.08 % versus
16.67±1.15 %; p<0.05, Fig. 6c, f). Similarly, in Hep3B
Fig. 2 Autophagy inhibition by
3-MA or CQ promotes apopto-
sis of SMMC-7721 cells during
nutrient starvation. SMMC-
7721 cells were cultured in
nutrient-starved medium and
treated with CQ (20 mM) or 3-
MA (10 mM) for 24 h. a After
being transfected with GFP-
tagged LC3 for 24 h, SMMC-
7721cells were treated as men-
tioned above, followed by
fluorescence microscopy (left
side, scale bar, 50 μm). The
right side is quantitative analy-
sis of GFP-LC3 punctate dots/
cell. b Cell viability was deter-
mined by a WST-8 assay. c Cell
morphology is shown (scale
bar, 50 μm). d Apoptotic cells
were captured by DAPI staining
of the condensed and frag-
mented nuclei. The arrow indi-
cates apoptotic cells (left side,
scale bar, 50 μm). The right
side is quantitative analysis of
apoptotic cells. e Analysis of
Annexin-V and PI staining. The
Annexin V+/PI− or Annexin V+/
PI+ cells were considered apo-
ptotic cells. Data of three repli-
cates are shown as means±SD.
*(p<0.05), **(p<0.01),
***(p<0.001). FN: full nutrient,
NF: nutrient-free
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xenograft tumor model, combined treatment with bevacizumab
and chloroquine also impaired tumor cell proliferation and
increased intratumoral apoptosis (Supplementary Fig. 3c–3e).
These results suggest that impaired cell proliferation and
increased cell apoptosis contribute to the tumor-suppressive
function of bevacizumab and CQ combination treatment.
ROS generation is enhanced and contributes to cell death
in nutrient-deficient HCC cells during autophagy inhibition
Metabolic stress causes ROS accumulation and increased ROS
leads to cell death. To determine the role of ROS in cell death of
nutrient-deficient HCC cells after autophagy inhibition, we first
detected whether autophagy could modulate ROS generation in
nutrient-deficient cells. Intracellular levels of ROS in HCC cells
following treatment with CQ, nutrient-starved medium, hypox-
ia, or the combination for indicated time (nutrient starvation for
24 h; hypoxia for 36 h) were examined. In both SMMC-7721
and Hep3B cell lines, there were marked increases in the ROS
levels after treatment with CQ and nutrient starvation or hypoxia
when compared with cells under nutrient starvation, hypoxia, or
CQ treatment alone (Fig. 7a,e). To evaluate whether enhanced
ROS levels may contribute to the cell death of nutrient-deficient
HCC cells with autophagy inhibition, we applied the antioxidant
NAC to eliminate ROS. SMMC-7721 and Hep3B cells pre-
treated with NAC displayed significantly reduced cell death
with CQ and nutrient starvation or hypoxia combined treatment
(Fig. 7b, c, f, and g). Thus, increased ROS levels have an
important role in the induction of cell death by nutrient defi-
ciency in combination with autophagy inhibitor. We also exam-
ined the immunostaining of 8-hydroxydeoxyguanosine (8-
OHdG) in xenograft tumor tissue, as 8-OHdG is an indicator
of DNA oxidative damage. As shown in Fig. 7d and h, more 8-
OHdG-positive cells were observed in the bevacizumab and CQ
cotreatment group. Together, these results suggest that autoph-
agy inhibition enhances metabolic stress-induced oxidative
damage, which contributes to the death of nutrient-starved
HCC cells.
Discussion
We report here that bevacizumab treatment inhibits the growth
of xenograft tumors and activates autophagy by reducing the
formation of new blood vessels. The combination of autoph-
agy inhibitor and bevacizumab treatment further inhibited
Fig. 3 3-MA promotes the
apoptosis of Hep3B cells during
nutrient starvation. Hep3B cells
were cultured in nutrient-
starved medium and treated
with 3-MA (10 mM) for 24 h. a
After transfection with GFP-
tagged LC3 for 24 h, Hep3B
cells were treated as mentioned
above, and images were taken
under a fluorescence micro-
scope(scale bar, 50 μm). b Cell
morphology is shown (scale
bar, 50 μm). c Apoptotic cells
were captured by DAPI staining
of the condensed and frag-
mented nuclei. The arrow indi-
cates apoptotic cells (scale bar,
50 μm). d Analysis of Annexin-
V and PI staining. Annexin V+/
PI− or Annexin V+/PI+ cells
were considered apoptotic cells.
e Quantitative analysis of GFP-
LC3 punctate dots/cell of a. f
Cell viability was determined
by a WST-8 assay. (g) Quanti-
tative analysis of apoptotic cells
of d. Data of three replicates are
shown as mean±SD. **(p<
0.01), ***(p<0.001). FN: full
nutrient, NF: nutrient-free
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HCC xenograft tumor growth, with enhanced apoptosis and
impaired cell proliferation. In addition, autophagy inhibition
led to enhanced ROS generation in nutrient-deficient HCC
cells in vitro and increased DNA oxidative damage in vivo.
Our results suggest that autophagy modulates ROS generation
and contributes to cell survival under metabolic stress; thus,
inhibition of autophagy may be a novel way to increase the
efficicacy of antiangiogenic agents in treating HCC.
Antiangiogenic strategy deprives tumors of their blood supply
by reducing the tumor vasculature, which leads to the induction
of necrosis or apoptosis in tumor cells, ultimately inducing tumor
regression [18]. In this study, bevacizumab treatment inhibited
the growth of tumor xenografts and activated autophagy by
reducing blood vessel generation. However, bevacizumab treat-
ment was not able to induce autophagy in HCC cells in vitro.
Autophagy can be activated by metabolic stress[19]. Thus, the
Fig. 4 SiBeclin1 reduces cell viability and promotes apoptosis of
HCC cells during hypoxic stress. After transfection with the siBeclin1
for 1 day, SMMC-7721 and Hep3B cells were cultured under normoxia
(20 % O2) or hypoxia (1 % O2) for 36 h. a HCC cells were transfected
with a GFP-tagged LC3 plasmid, and images were taken under a
fluorescence microscope (scale bar, 50 μm). b Cell morphology was
captured by a light microscope (scale bar, 50 μm). c Apoptotic cells
were detected by DAPI staining. Arrows indicate the apoptotic cell
(scale bar, 50 μm). d, e Quantitative analysis of GFP-LC3 punctate
dots/cell of a. f, g Quantitative analysis of apoptotic cells of c. Data
represent the mean of three independent experiments and are shown as
mean±SD. *(p<0.05), **(p<0.01), ***(p<0.001). si-NT: no target
siRNA. N: normoxia, H: hypoxia
Fig. 5 Therapeutic efficacy of bevacizumab was enhanced by CQ in
hepatocarcinoma xenograft model. Tumor models were established. a
SMMC-7721 tumor xenografts were treated with CQ or a combination
of CQ and bevacizumab. Immunohistochemical staining for CD31 (a
and b) and LC3 (c and d) was detected. Representative electron
microscopic images of autophagosome (e and f) are shown. An arrow
indicates the autophagosome (scale bar, 100 μm). b Body weights of
all mice were measured every 4 days. c Tumor progression was
evaluated by measuring tumor volume every 4 days. d After 21 days
of treatment, mice were sacrificed, and tumor weights were measured.
Data represent the mean of three independent experiments and are
shown as mean±SD. *(p<0.05), **(p<0.01). Beva: bevacizumab
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upregulation of autophagy during bevacizumab treatment is a
response of xenograft tumor cells to metabolic stress.
Under nutrient deficiency, autophagy is induced and pro-
motes tumor cell survival [20, 21]. Consistent with this, we
demonstrated here that autophagy protected HCC cells from
nutrient starvation and hypoxia-induced apoptosis in vitro.
Interestingly, early reports have shown that autophagy acti-
vated by hypoxia can mediate the tolerance of hepatocellular
carcinoma cells to nutrient deprivation [22]. Autophagy pro-
motes cell survival in various ways, such as providing energy
substrates, mitigating accumulated ROS, and reducing dam-
aged organelles [20]. In fact, in the early or later stages of
tumor progression, autophagy is activated in metabolically
stressed tumor regions [23]. These findings suggest that main-
taining cell survival by autophagy in unfavorable conditions is
essential for tumor development. Thus, we suspect that inhi-
bition of autophagy may be an effective way of improving
antiangiogenic strategy in vivo. In this study, we observed that
the combined treatment of bevacizumab and CQ led to dra-
matic tumor repression. These results indicate that inhibition
of autophagy impairs the survival mechanism of tumors and
intensifies metabolic stress, consequently leading to tumor
inhibition. Indeed, previous studies have shown that endothe-
lial cells initiate autophagy as a survival mechanism against
angiogenesis inhibitor-induced apoptosis [24, 25]. These find-
ings further strengthen our hypothesis that autophagy inhibi-
tion can enhance the therapeutic efficacy of antiangiogenic
strategy. In this study, we showed that the enhancement of
apoptosis and impairment of cell proliferation are most likely
the mechanisms underlying the antitumor effects of combined
bevacizumab and CQ treatment. Meanwhile, inhibition of
autophagy may impair its function of preserving organelle
required for cell growth [20] and render cell cycle arrest [26].
It was suggested that low concentrations of ROS promoted
cell proliferation [27], but high ROS concentrations lead to cell
death [28]. Therefore, modulation of intracellular ROS levels is
critical for cancer cell survival, as metabolic stress causes ROS
accumulation [29, 30]. In this study, we observed a modest
increase in cellular ROS generation in nutrient-starved and
hypoxic HCC cells. However, the combination of CQ treatment
and nutrient starvation or hypoxia resulted in a marked increase
in ROS generation. Increased levels of ROS contributed to cell
Fig. 6 Combination treatment of bevacizumab and CQ leads to re-
duced cell proliferation and increased apoptosis in a hepatocarcinoma
xenograft tumor model. a, b Immunohistochemical staining of repre-
sentative tumor tissue samples with PCNA and activated caspase-3
antibodies(scale bar, 100 μm). c Apoptosis of tumor tissues was
measured by TUNEL assays; green nucleus shows TUNEL-positive
cells(scale bar, 100 μm). d, e Quantitative analysis of proliferative and
caspase-3-activated cells. f Quantitative analysis of TUNEL-positive
cells. Data represent three independent experiments shown as mean±
SD. *(p<0.05), **(p<0.01). Beva: bevacizumab
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death in nutrient-starved or hypoxic HCC cells when autophagy
was inhibited, but treatment with the NAC antioxidant mark-
edly reduced this phenonemon. Consistent with our findings, a
recent study suggested that induction of autophagy could de-
crease ROS levels and moderate ROS-induced cell death [30].
The removal of oxidatively damaged organelles and proteins by
autophagy provides a second level of protection against oxida-
tive stress [31]. However, the interaction between ROS and
autophagy is complex. ROS, especially mitochondrial ROS,
serve as signaling molecules in inducing autophagy [32, 33].
Although angiogenesis inhibitors were considered as
desirable anticancer agents, it was found that most
tumors were still resistant to antiangiogenesis [34, 35].
The mechanisms of resistance to antiangiogenesis are
still unknown [34, 35]. In this study, we provide com-
pelling data suggesting that inhibition of autophagy can
enhance the tumor-suppressive function of bevacizumab.
Thus, activation of autophagy may be involved in resis-
tance to antiangiogenic strategies. Autophagy may help
tumor cells mitigate metabolic stress and promote cell
survival during antiangiogenesis, which may provide
tumor cells with a greater change to develop other ways
to resist antiangiogentic therapy. In conclusion, we show
that inhibition of autophagy may be a novel way to
increase the efficicacy of antiangiogenic agents in the
treatment of HCC.
Fig. 7 ROS generation is augmented and contributes to cell death in
nutrient-deficient HCC cells when autophagy is inhibited. SMMC-
7721 and Hep3B cells were incubated in nutrient-starved medium for
24 h or hypoxia for 36 h with 10 μM CQ. a, e Cellular ROS generation
was determined using DCF-DA staining (scale bar, 100 μm). b, c, f, g
Cells were pretreated with 10 mM NAC for 2 h; then cells were
incubated in EBSS medium or hypoxia alone or with 10 μM CQ for
the indicated time. Cell viability was determined by a WST-8 assay.
Data shown are mean±SD from at least three independent experiments.
d, h Immunohistochemical staining of 8-OhdG (scale bar, 100 μm).
FN: full nutrient, NF: nutrient-free, N: normoxia, H: hypoxia
J Mol Med (2013) 91:473–483 481
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